Marshall Wace
ACRV icon

Marshall Wace’s Acrivon Therapeutics ACRV Stock Holding History

Marshall Wace’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$947K Sell
531,856
-28,580
-5% -$48.5K ﹤0.01% 2216
2026
Q1 		$779K Buy
560,436
+64,355
+13% +$112K ﹤0.01% 2248
2025
Q4 		$1.2M Buy
496,081
+346,366
+231% +$753K ﹤0.01% 1843
2025
Q3 		$271K Sell
149,715
-31,472
-17% -$44.2K ﹤0.01% 2468
2025
Q2 		$216K Sell
181,187
-269,204
-60% -$369K ﹤0.01% 2440
2025
Q1 		$914K Sell
450,391
-147,403
-25% -$794K ﹤0.01% 1822
2024
Q4 		$3.6M Sell
597,794
-212,065
-26% -$1.54M ﹤0.01% 1208
2024
Q3 		$5.67M Sell
809,859
-139,007
-15% -$1.1M 0.01% 947
2024
Q2 		$5.5M Buy
948,866
+351,397
+59% +$2.83M 0.01% 957
2024
Q1 		$4.27M Hold
597,469
– – 0.01% 1060
2023
Q4 		$2.94M Hold
597,469
– – 0.01% 1082
2023
Q3 		$5.71M Hold
597,469
– – 0.01% 823
2023
Q2 		$7.74M Hold
597,469
– – 0.02% 845
2023
Q1 		$7.58M Sell
597,469
-625,783
-51% -$10.5M 0.02% 812
2022
Q4 		$14.1M Buy
+1,223,252
New +$15.5M 0.03% 624

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's ACRV Position: Q2 2026 in Review

Marshall Wace reduced its Acrivon Therapeutics (ACRV) stake by 5.1% in Q2 2026, selling an estimated $48.5K and leaving 531,856 shares worth $947K. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Marshall Wace first reported a position in ACRV in Q4 2022 and has held it in 15 quarters since. The position peaked at $14.1M in Q4 2022. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Marshall Wace held 531,856 shares of Acrivon Therapeutics worth $947K as of Q2 2026.
  • Marshall Wace sold 28,580 Acrivon Therapeutics shares in Q2 2026, an estimated $48.5K.
  • Acrivon Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2216 holding.
  • Marshall Wace first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Marshall Wace's Acrivon Therapeutics position peaked at $14.1M in Q4 2022.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.